cvs health glp-1 receptor agonists weight management diabetes treatments Cardiovascular Protective Properties of Agonists: More than Just Diabetic and Loss Drugs GLP-1 Business Report for Healthtech

Rosenkilde, Jonathan E

Currently, those with alcohol and substance use disorders (ASUDs) receive behavioural, motivational, and cognitive treatment, but the number of approved medications is somewhat limited

Classic examples include native GLP-1, which has a plasma half-life of approximately 2 minutes and required continuous infusion in early studiesan impractical route for chronic therapyyet was subsequently transformed into a once-weekly therapeutic through lipidation and albumin-binding strategies (Drucker, 2018)

Br J Pharmacol 179(4):659676 Hernandez AF, Green JB, Janmohamed S, DAgostino Sr RB, Granger CB, Jones NP, et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Once primarily a concern for high-income countries, excess weight and obesity is now widespread across many different regions, income levels and age groups, making it one of the worlds biggest public health concerns

Retained gastric contents, increased gastric volume, endoscopy discontinuation, regurgitation, aspiration events, aspiration pneumonitis, aspiration pneumonia, and postoperative respiratory failure are related but not interchangeable endpoints